Amgen has stopped a Phase 3 trial of its monoclonal antibody for metastatic pancreatic cancer after the independent data monitoring committee concluded the drug was unlikely to show improved overall survival compared with gemcitabine. ---Subscribe to MedNous to access this article--- Clinical Research Company News
